KORU Medical Systems (NASDAQ:KRMD) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of KORU Medical Systems (NASDAQ:KRMD) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock.

KRMD has been the subject of a number of other reports. Lake Street Capital boosted their target price on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. B. Riley Financial increased their price target on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 12th. Craig Hallum restated a “buy” rating and set a $7.00 price objective on shares of KORU Medical Systems in a report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, KORU Medical Systems currently has a consensus rating of “Moderate Buy” and an average price target of $6.50.

KORU Medical Systems Trading Down 0.7%

KRMD opened at $4.28 on Friday. KORU Medical Systems has a 1-year low of $1.86 and a 1-year high of $6.61. The company has a current ratio of 2.48, a quick ratio of 1.92 and a debt-to-equity ratio of 0.01. The company has a market cap of $198.25 million, a P/E ratio of -71.33 and a beta of 0.47. The company has a fifty day moving average price of $5.10 and a two-hundred day moving average price of $4.79.

KORU Medical Systems (NASDAQ:KRMD) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01. The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $10.90 million. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 16.04%. Analysts predict that KORU Medical Systems will post -0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On KORU Medical Systems

Several large investors have recently added to or reduced their stakes in the business. Simcoe Capital LLC bought a new position in shares of KORU Medical Systems in the fourth quarter valued at approximately $3,921,000. Geode Capital Management LLC grew its holdings in KORU Medical Systems by 101.3% during the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock worth $3,571,000 after buying an additional 501,875 shares in the last quarter. Acuitas Investments LLC grew its holdings in KORU Medical Systems by 89.6% during the third quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock worth $2,923,000 after buying an additional 360,594 shares in the last quarter. First Light Asset Management LLC raised its position in KORU Medical Systems by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock valued at $16,760,000 after buying an additional 226,700 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in KORU Medical Systems by 189.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock valued at $617,000 after buying an additional 158,914 shares during the last quarter. Institutional investors own 58.60% of the company’s stock.

Key KORU Medical Systems News

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and maintained a “buy” rating, implying roughly an 87% upside from the current price — a meaningful vote of confidence from a major dealer. Benzinga
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and set a $6.00 target (≈40% upside), adding further analyst support for upside to the stock. Benzinga
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — clear regulatory progress that should aid European commercialization and recurring revenue potential. Las Vegas Sun
• Positive Sentiment: Q4 2025 results beat EPS expectations (loss of $0.01 vs. -$0.02 est.), reported ~20% revenue growth and positive adjusted EBITDA; management also initiated FY2026 guidance with revenue of $47.5M–$50.0M (roughly in line with consensus ~ $48.8M). These operational improvements support medium-term growth prospects. Business Wire – Q4 & Guidance
• Neutral Sentiment: Analysts and the company provided forward revenue guidance but EPS guidance detail was not clearly disclosed in public summaries; revenue range is encouraging but leaves some near-term visibility questions. Q4 Press Release / Slide Deck
• Negative Sentiment: KORU announced a CEO transition: long-time CEO Linda Tharby will retire June 30 and the board appointed Adam Kalberma as successor. Leadership changes introduce short-term execution risk and can pressure the stock until the market judges the new CEO. Business Wire – CEO Transition
• Negative Sentiment: Despite positives, KRMD still shows a negative net margin and negative ROE; valuation and profitability concerns may keep selling pressure, which likely explains why the stock is trading lower even after upgrades and regulatory wins.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.